Three new treatment options made available for cancer patients in Scotland.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.
We spoke to Dr Kate Cwynarski, who led the Stand Up To Cancer-funded MARIETTA trial, a clinical trial which details a “potentially transforming” treatment for some patients with secondary CNS lymphoma.
The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.
Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy.
The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.
The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.
New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.